Glucose-regulated insulin secretion is a critical function of beta cells which is lost in type I diabetics due to autoimmune reaction against beta cells. The discovery of novel methods for differentiation of functional beta cells enhances the potential use of the Company's stem cell lines for cell therapy of diabetes.

Type I diabetes mellitus affects about 15 million people worldwide and may be successfully treated by transplantation of beta islet cells. However, there is insufficient supply of transplantable materials to treat the number of afflicted patients and discovery of viable methods to increase the number of available beta islets for transplantation is a major goal of diabetes research. The Company's stem cell lines and associated differentiation methods represent a potential indefinite supply of human beta cells for use in transplantation into diabetic patients.

The Company has recently updated and formalized its patent filing with the USPTO and also filed an application seeking international patent protection for its novel stem cell generation and differentiation methods, certain compositions and the use of these stem cells or stem cell-derived beta islet cells in the treatment of human and animal diabetes.

Dr. Jim Musick, Vitro's Chairman of the Board and Chief Operating Officer, said, "We are pleased to have expanded the capability of our adult beta islet stem cells to include differentiation into functional beta cells that may have potential for transplantation therapy of diabetes. We plan to add stem cell-derived beta islet cells and derivatives to our VITROCELL(TM) product line in the near future. Our goal is to make available beta islet stem cell lines that will contribute to advancing current therapy of diabetes."

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG - News), http://www.vitrodiag.com, founded in 1986, is a biotechnology company that developed and manufactures the VITROCELL(TM) brand of human cell lines consisting of pituitary and pancreatic-derived cell lines and related products for various research and commercial applications. The Company also owns proprietary stem cell technology with potential application in the treatment of animal and human diabetes, as described above.

Safe Harbor Statement

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s Annual Report on Form 10-KSB for the fiscal year ended October 31, 2004 under the caption, “Risk Factors.” Most these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Vitro Diagnostics, Inc.